Viridian Therapeutics, Inc./DE Earnings Per Share (Basic)
Viridian Therapeutics, Inc./DE (VRDN) reported Earnings Per Share (Basic) of -$1.15 per share for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2024-11-12
- Viridian Therapeutics, Inc./DE earnings per share, basic for the quarter ending 2024-09-30 was -$1.15.
- Viridian Therapeutics, Inc./DE earnings per share, basic for the quarter ending 2024-06-30 was -$1.02.
- Viridian Therapeutics, Inc./DE earnings per share, basic for the quarter ending 2024-03-31 was -$0.79.
- Viridian Therapeutics, Inc./DE earnings per share, basic for the quarter ending 2023-09-30 was -$1.09.
- Viridian Therapeutics, Inc./DE earnings per share, basic for fiscal 2023 was -$5.31.
- Viridian Therapeutics, Inc./DE earnings per share, basic for fiscal 2022 was -$4.05.
- Viridian Therapeutics, Inc./DE earnings per share, basic for fiscal 2021 was -$6.66.
- Viridian Therapeutics, Inc./DE earnings per share, basic for fiscal 2020 was -$31.13.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$1.15 10-Q · filed 2024-11-12 | -$2.98 10-Q · filed 2024-11-12 | ||
| 2024-06-30 | -$1.02 10-Q · filed 2024-08-08 | -$1.82 10-Q · filed 2024-08-08 | ||
| 2024-03-31 | -$0.79 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | -$5.31 10-K · filed 2024-02-27 | |||
| 2023-09-30 | -$1.09 10-Q · filed 2024-11-12 | -$3.97 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | -$1.27 10-Q · filed 2024-08-08 | -$2.88 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$1.61 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$4.05 10-K · filed 2024-02-27 | |||
| 2022-09-30 | -$0.86 10-Q · filed 2023-11-13 | -$2.88 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | -$1.06 10-Q · filed 2023-08-08 | -$2.05 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$0.98 10-Q · filed 2023-05-10 | -$2.26 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$3.46 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$5.12 derived: net income ÷ weighted average shares · filed 2024-02-27 |
| 2021-12-31 | -$1.30 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$2.57 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$4.41 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$6.66 10-K · filed 2024-02-27 |
| 2021-09-30 | -$1.25 10-Q · filed 2022-11-14 | -$3.32 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$5.95 10-Q · filed 2022-11-14 | -$19.11 derived: net income ÷ weighted average shares · filed 2022-11-14 |
| 2021-06-30 | -$2.21 10-Q · filed 2022-08-15 | -$5.04 10-Q · filed 2022-08-15 | -$20.76 derived: net income ÷ weighted average shares · filed 2022-08-15 | -$24.01 derived: net income ÷ weighted average shares · filed 2022-08-15 |
| 2021-03-31 | -$2.91 10-Q · filed 2022-05-13 | -$21.26 derived: net income ÷ weighted average shares · filed 2022-05-13 | -$24.59 derived: net income ÷ weighted average shares · filed 2022-05-13 | -$27.64 derived: net income ÷ weighted average shares · filed 2022-05-13 |
| 2020-12-31 | -$23.06 derived: net income ÷ weighted average shares · filed 2022-03-11 | -$25.14 derived: net income ÷ weighted average shares · filed 2022-03-11 | -$27.52 derived: net income ÷ weighted average shares · filed 2022-03-11 | -$31.13 10-K · filed 2022-03-11 |
| 2020-09-30 | -$1.48 10-Q · filed 2021-11-05 | -$3.29 derived: net income ÷ weighted average shares · filed 2021-11-05 | -$5.82 10-Q · filed 2021-11-05 | |
| 2020-06-30 | -$1.82 10-Q · filed 2021-08-12 | -$4.41 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |